Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that ER negative, HER2-negative, PR negative status confers therapeutic sensitivity to Capecitabine in patients with Invasive Breast Carcinoma.
The Republic of Ireland's Health Service Executive (HSE) has approved capecitabine for reimbursement as a treatment option for the adjuvant treatment of stage I to IIIB triple negative breast cancer (TNBC) in patients with residual invasive disease after neoadjuvant chemotherapy treatment.
This statement is based on a regulatory approval from the Health Service Executive:
Adjuvant treatment of stage I to IIIB, triple negative breast cancer (TNBC) in patients with residual invasive disease after neoadjuvant chemotherapy treatment.